Stockscreener 앱 받기
8.92
1.76%
-0.16
시간 외 거래:
8.92
전일 마감가:
$9.08
열려 있는:
$9.01
하루 거래량:
386.90K
Relative Volume:
0.81
시가총액:
$521.93M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-2.4173
EPS:
-3.69
순현금흐름:
$-134.48M
1주 성능:
+4.82%
1개월 성능:
-6.99%
6개월 성능:
-50.31%
1년 성능:
-47.47%
1일 변동 폭
$8.655
$9.38
1주일 범위
$7.95
$9.38
52주 변동 폭
$7.95
$30.19
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.92 | 521.93M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat
Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World
Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World
Cullinan Therapeutics Inc (CGEM) Reports Q4 2024 Net Loss of $47 - GuruFocus.com
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Cullinan Therapeutics: Q4 Earnings Snapshot - The Pioneer
Cullinan Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics CEO sells $106,872 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock - Investing.com India
Cullinan Therapeutics CEO sells $106,872 in stock - Investing.com India
Cullinan Therapeutics' chief medical officer sells $41,754 in stock - Investing.com
Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024 - Nasdaq
Cullinan Therapeutics, Inc. SEC 10-K Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire Inc.
Financial Review: Cullinan Therapeutics (NASDAQ:CGEM) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Exclusive Access: Cullinan Therapeutics Leadership Reveals Strategy at Elite Healthcare Forums - StockTitan
Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News
CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month LowHere's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Analysts - MarketBeat
FY2024 Earnings Estimate for CGEM Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Forecast for CGEM FY2024 Earnings? - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings? - Defense World
Ratio Revelations: Cullinan Therapeutics Inc (CGEM)’s Financial Metrics in the Spotlight - The Dwinnex
CGEM Stock Sees Decline of Approximately -5.74% in Last Five Days - Knox Daily
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach - Fierce Biotech
SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World
HC Wainwright Boosts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $33.00 - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for CGEM Issued By HC Wainwright - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cullinan reports zipalertinib study met primary endpoint - MSN
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):